STOCK TITAN

Revvity, Inc. - RVTY STOCK NEWS

Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.

Revvity, Inc. (RVTY) is a leading company dedicated to enhancing human and environmental health. The company collaborates with scientists, clinicians, and government agencies to develop more effective diagnostics and therapies. Additionally, Revvity ensures the safety of our food and air by detecting contaminants that could harm the environment and public health.

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions. The Diagnostics segment focuses on areas such as immunodiagnostics, reproductive health, and applied genomics. This division provides crucial tools and tests for genetic screening and various health diagnostics. Meanwhile, the Discovery & Analytical Solutions segment addresses life science research and industrial applications, offering products and services for environmental and food analysis, as well as informatics and enterprise software solutions.

In recent achievements, Revvity has been at the forefront of developing innovative solutions that transform raw data into actionable insights, thus improving public health and environmental safety. The company’s systems are instrumental in rapidly detecting both known and unknown contaminants in food, water, and air. They also play a critical role in ensuring compliance with health and safety standards.

Revvity's partnerships span across the pharmaceutical, biomedical, chemical, environmental, and industrial markets, making it a versatile player in multiple sectors. The company’s commitment to quality and innovation has led to significant advancements in research and diagnostics, making it a key contributor to global health and safety.

Rhea-AI Summary
Revvity, Inc. (RVTY) will release its Q1 2024 financial results on April 29, 2024, followed by a conference call hosted by the CEO and CFO. Investors can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) has been granted a preliminary injunction by the Massachusetts Superior Court against Cloud Software Group (CSG) for breaching contractual obligations. The injunction mandates CSG to cease all activities in Revvity's exclusive markets and continue maintenance services for Spotfire® software. Revvity emphasizes its dedication to customer service and satisfaction, ensuring uninterrupted service for its customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (RVTY) files a complaint against Cloud Software Group for breaching strategic partnership obligations related to Spotfire® software. Revvity reaffirms 2024 revenue guidance amidst legal dispute.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ChemDraw, a cutting-edge chemistry suite enhancing research productivity and collaboration in chemical, pharmaceutical, and biotechnology industries. The software aims to streamline communication of complex chemical concepts, promote interdisciplinary cooperation, and boost research efficiency. Signals ChemDraw offers intuitive design, advanced features, and cloud-native architecture, catering to the evolving needs of the scientific community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at several investor conferences in February and March 2024, providing updates on the company's strategic priorities. Key executives like Max Krakowiak and Prahlad Singh will discuss the financial and operational aspects at these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ClinicalTM, a centralized data science platform integrated with Spotfire for efficient clinical study data management, enabling quick clinical decisions and therapeutic advancements. The platform emphasizes cross-functional collaboration, customization, and scalability to enhance clinical research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) reported a 6% decline in fourth quarter revenue, with a GAAP EPS of $0.64 and adjusted EPS of $1.25. The full year 2023 saw a 17% decrease in revenue and a 59% decrease in GAAP EPS compared to 2022. The company initiated full year 2024 guidance of $2.79-$2.85 billion in revenue and adjusted EPS of $4.55-$4.75. The life sciences segment experienced an 8% decrease in revenue for Q4 2023, while the diagnostics segment saw a 4% decrease. The company's financial performance reflects a challenging year and uncertain future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announced the election of Sophie Vandebroek and Michael Klobuchar to its board of directors, effective February 1, 2024. Vandebroek brings expertise in AI, business processes, sustainability, and cybersecurity, with a background in global organizations and academic advisory. Klobuchar, an executive at Merck & Co. Inc., has extensive experience in strategic and operational initiatives for global enterprises, M&A activities, and leadership in research and development. The company also expressed gratitude to Dr. Sylvie Gregoire for her service on the board since 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
management
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) has announced a regular quarterly dividend of $0.07 per share of common stock, payable on May 10, 2024, to shareholders of record at the close of business on April 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
dividends
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announces Q4 2023 financial results, including a revenue decline of -7% and -4% in organic revenue. Full year 2023 adjusted earnings per share expected to meet or exceed guidance. Prahlad Singh to present at J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags

FAQ

What is the current stock price of Revvity (RVTY)?

The current stock price of Revvity (RVTY) is $112.03 as of November 22, 2024.

What is the market cap of Revvity (RVTY)?

The market cap of Revvity (RVTY) is approximately 13.5B.

What does Revvity, Inc. specialize in?

Revvity specializes in improving human and environmental health through diagnostics, therapies, and contaminant detection.

What are the main segments of Revvity?

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions.

What services does Revvity provide?

Revvity provides instruments, tests, services, and software solutions for pharmaceutical, biomedical, chemical, environmental, and industrial markets.

How does Revvity contribute to environmental health?

Revvity helps detect contaminants in food, water, and air, ensuring compliance with health and safety standards.

What recent achievements has Revvity made?

Revvity has developed innovative solutions that transform data into actionable insights, improving public health and safety.

What industries does Revvity serve?

Revvity serves pharmaceutical, biomedical, chemical, environmental, and general industrial markets.

What are some key products offered by Revvity?

Key products include genetic screening tools, environmental analytical instruments, and informatics software.

How does Revvity support life science research?

Revvity provides life science research instrumentation and diagnostic lab services to advance health and scientific understanding.

Who are Revvity's primary partners?

Revvity partners with scientists, clinicians, government agencies, and industries to improve diagnostics and environmental health.

How does Revvity ensure the safety of food and air?

Revvity uses advanced systems to detect contaminants and monitor the quality of food and air, ensuring compliance with safety standards.

Revvity, Inc.

NYSE:RVTY

RVTY Rankings

RVTY Stock Data

13.53B
121.36M
0.29%
91.94%
3.44%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
WALTHAM